The hospital received a five-year $5 million grant from CDC to survey for communicable diseases in children and evaluate vaccine effectiveness.
The Children’s Hospital of Pittsburgh of UPMC announced on Sept. 29, 2016 that it has received a $5 million, five-year, grant from the United States Centers for Disease Control and Prevention (CDC) to join the New Vaccine Surveillance Network (NVSN). The hospital joins a group of medical centers nationwide that survey for communicable disease in children and evaluate vaccine effectiveness.
“There are few or no effective antivirals for these viruses, and therefore vaccination is the most promising intervention,” John V. Williams, MD, chief, Division of Infectious Diseases at Children’s and principal investigator of the new NVSN site said in a statement. “Active disease surveillance is necessary to establish the effectiveness of existing vaccines and provide the data needed to guide policymakers and pharmaceutical industries in the development of new vaccines. We intend to provide that critical information.”
The children’s hospital site of the NVSN has three aims:
The NVSN has been funded by the CDC since 2000, becoming a core component of national influenza surveillance. The University of Pittsburgh’s Vaccination Research Group provides additional information on a broader, primarily adult population of people seen at UPMC outpatient facilities for potential influenza.
Source: Children’s Hospital of Pittsburgh
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.